Abstract Number: L18 • 2019 ACR/ARP Annual Meeting
A Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), Telitacicept (RC18), in Systemic Lupus Erythematosus (SLE): Results of a Phase 2b Study
Background/Purpose: Telitacicept, also named RC18, is a novel recombinant fusion protein constructed with the extracellular domain of the human transmembrane activator and calcium modulator and…Abstract Number: 1 • 2018 ACR/ARHP Annual Meeting
Profiling of B-Cell Related Factors and Its Decoy Receptors in Rheumatoid Arthritis: Potential Clues for Patient Stratification
Background/Purpose: B-cell over-activation plays a key role in the pathogenesis of rheumatoid arthritis (RA), thus being recognized as a therapeutic target. However, the activation of…Abstract Number: 1765 • 2018 ACR/ARHP Annual Meeting
Cerebrospinal Fluid Biomarker of Disease Activity: Significance in ANCA-Related Hypertrophic Pachymeningitis
Background/Purpose: Hypertrophic pachymeningitis (HP), which becomes the cause of chronic headache, seizure, and cranial neuropathy, is an inflammatory disorder demonstrating focal and diffuse thickening of…Abstract Number: 2642 • 2018 ACR/ARHP Annual Meeting
Atacicept Dose Rationale for a Phase 3 Study in Patients with High Disease Activity and Auto-Antibody Positive SLE
Background/Purpose: Atacicept targets the B-cell-stimulators BLyS and APRIL, and is in development for the treatment of patients (pts) with SLE. Here, we integrated non-clinical and…Abstract Number: 2678 • 2018 ACR/ARHP Annual Meeting
Integrated Safety Profile of Atacicept from All Clinical Studies to Date
Background/Purpose: We conducted an integrated analysis of pooled safety data from all 17 atacicept clinical studies to date, across multiple indications, to further define atacicept’s…Abstract Number: 28 • 2017 ACR/ARHP Annual Meeting
Sapril and Sbcma As Potential Biomarkers of B Cell Hyperactivation in Rheumatoid Arthritis: A Cluster Analysis Approach
Background/Purpose: B cell compartment plays a key role in the pathogenesis of rheumatoid arthritis (RA). Activation and survival of B cell largely rely on the…Abstract Number: 889 • 2017 ACR/ARHP Annual Meeting
Attainment of Low Disease Activity By Patients with Systemic Lupus Erythematosus Starting with High Disease Activity in a 24-Week, Randomized, Placebo-Controlled, Phase IIb Study of Atacicept (ADDRESS II)
Background/Purpose: Low disease activity (LDA) in lupus patients is increasingly a goal of treatment. For instance, Lupus Low Disease Activity State (LLDAS) attainment is associated…Abstract Number: 2585 • 2017 ACR/ARHP Annual Meeting
Safety Profile in SLE Patients Treated with Atacicept in a Phase IIb Study (ADDRESS II) and Its Extension Study
Background/Purpose: Atacicept targets the B-cell stimulating factors, BLyS and APRIL, and has demonstrated a clinical response in SLE patients (pts) with high disease activity (HDA;…Abstract Number: 2586 • 2017 ACR/ARHP Annual Meeting
Exposure-Response Modelling and Exposure-Safety Modelling Analyses in Two Phase II Studies of Atacicept in SLE
Background/Purpose: Atacicept targets the B-cell stimulating factors BLyS and APRIL, and has been shown to reduce SLE disease activity. Our analyses evaluated the exposure-response and…Abstract Number: 654 • 2016 ACR/ARHP Annual Meeting
The Level of B-Cell Active Cytokines and Soluble B-Cell Activating Factor/a Proliferation-Inducing Ligand Receptors in Patients with Primary Sjogren’s Syndrome
Background/Purpose: Primary Sjögren`s syndrome (pSS) is an autoimmune diseases characterized by lymphocytic infiltration of exocrine glands and dysregulated proliferation and differentiation of B cells. Two…Abstract Number: 1109 • 2015 ACR/ARHP Annual Meeting
Co-Crystal Structure of TACI and APRIL-BAFF-BAFF Heteromer Suggests That Charged Residues in APRIL and BAFF Dictate Their Receptor Binding Affinities
Background/Purpose: The human B cell survival factor, B cell activation factor (BAFF), and its closely related homologue, a proliferation-inducing ligand (APRIL), modulate B cell functions…Abstract Number: 1110 • 2015 ACR/ARHP Annual Meeting
A Proliferative Inducing Ligand (APRIL) Promotes IL-10 Production of Human B Cells
Background/Purpose: B cells may have a negative regulatory role, mainly mediated by interleukin 10 (IL-10). We recently showed that regulatory B-cell functions are impaired in…Abstract Number: 2838 • 2014 ACR/ARHP Annual Meeting
Exploratory Analysis of Pharmacokinetic Effects of Atacicept in Patients with Moderate to Severe Systemic Lupus Erythematosus
Background/Purpose: Atacicept is a fusion protein that inhibits B-cell stimulating factors BLyS and APRIL. We previously reported the clinical effects of atacicept in lupus patients…Abstract Number: 666 • 2014 ACR/ARHP Annual Meeting
Approach to Discriminate Treatment Impact in Both Moderate and Severe SLE: The Atacicept Phase IIb Trial Design
Background/Purpose Increases in background treatment in SLE trials lead to high placebo group responses in patients with moderate but not those with high disease activity…Abstract Number: 1591 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Atacicept For Prevention Of Flares In Subjects With Moderate To Severe Systemic Lupus Erythematosus (SLE)
Background/Purpose: Atacicept is a fusion protein that inhibits B-cell stimulation factors BLyS and APRIL. Levels of BLyS and APRIL are elevated in patients with SLE.…